Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Noemie Leblay, PhD, Ranjan Maity, PhD, Elie Barakat, Sylvia McCulloch, MD MSc, Peter Duggan, MD FRCPC, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-137650

Published: 2020

Journal Articles

Immune Deregulation in Active Multiple Myeloma

Paola Neri, MD

Blood (2020) 136 (Supplement 1): SCI5.

https://doi.org/10.1182/blood-2020-133077

Published: 2020

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

https://doi.org/10.1182/blood-2019-124191

Published: 2019

Journal Articles

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Paola Neri, MD PhD, Ranjan Maity, PhD, Jean-Baptiste Alberge, Sarthak Sinha, BSc, Justin Donovan, Madison Kong, Fajer Hasan, Arzina Jaffer, Lawrence H. Boise, PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 572.

https://doi.org/10.1182/blood-2019-127593

Published: 2019

Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 1793.

https://doi.org/10.1182/blood-2019-126828

Published: 2019

Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 686.

https://doi.org/10.1182/blood-2019-131981

Published: 2019

Journal Articles

Monoclonal Gammopathy of Clinical Significance - a Single Center Experience

Holly Lee, MD, Lesley Street, MD, Jason Tay, MD, Jennifer Grossman, MD, John F Thaell, MD, Dawn Goodyear, MD, Sylvia McCulloch, MD, Peter Duggan, MD, Paola Neri, MD, Victor Jimenez-Zepeda, MD

Blood (2018) 132 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2018-99-117819

Published: 2018

Journal Articles

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns

Holly Lee, MD, Lesley Street, MD, Jason Tay, MD, Jennifer Grossman, MD, John F Thaell, MD, Dawn Goodyear, MD, Sylvia McCulloch, MD, Peter Duggan, MD, Paola Neri, MD, Victor Jimenez-Zepeda, MD

Blood (2018) 132 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2018-99-117930

Published: 2018

Journal Articles

Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing

Paola Neri, MD, Ranjan Maity, PhD, Sylvia McCulloch, MD, Peter Duggan, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2018-99-117482

Published: 2018

Journal Articles

Enhancer Deregulation in Myeloma

Paola Neri, MD

Blood (2018) 132 (Supplement 1): SCI-38.

https://doi.org/10.1182/blood-2018-99-109523

Published: 2018

Journal Articles

Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients

Paola Neri, MD, Ranjan Maity, PhD, Ines Tagoug, PhD, Sylvia McCulloch, MD, Peter Duggan, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD, Anjan Thakurta, PhD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 242.

https://doi.org/10.1182/blood-2018-99-117531

Published: 2018

Journal Articles

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Benjamin G Barwick, PhD, Paola Neri, MD, Nizar Bahlis, MD, Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Vikas A. Gupta, MD PhD, Daniel Auclair, PhD, Jonathan J Keats, PhD, Sagar Lonial, MD, Paula M Vertino, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 405.

https://doi.org/10.1182/blood-2018-99-113585

Published: 2018

Journal Articles

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M Matulis, PhD, Vikas A. Gupta, MD PhD, Izabelle Brown, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Paola Neri, MD, Nizar Bahlis, MD, Jonathan L Kaufman, MD, Leonard Heffner, MD, Sagar Lonial, MD, Ajay K Nooka, MDMPH, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 952.

https://doi.org/10.1182/blood-2018-99-113504

Published: 2018

Journal Articles

FOXM1 Is Associated with Development of Therapeutic Resistance in Multiple Myeloma

Michael Amatangelo, PhD, Maria Ortiz, Paola Neri, MD, Fadi Towfic, PhD, Chad Bjorklund, Jian Kang, Erica Sternberg, Nizar J. Bahlis, MD, Matthew Trotter, PhD, Anjan Thakurta, PhD

Blood (2017) 130 (Supplement 1): 1261.

https://doi.org/10.1182/blood.V130.Suppl_1.1261.1261

Published: 2017

Journal Articles

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Paola Neri, MD, Ranjan Maity, PhD, Ines Tagoug, PhD, Peter Duggan, MD FRCPC, Sylvia McCulloch, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD FRCPC, Lawrence H. Boise, PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 123.

https://doi.org/10.1182/blood.V130.Suppl_1.123.123

Published: 2017

Journal Articles

Early Relapse in Transplant-Eligible MM Patients Undergoing Auto-SCT Followed By Maintenance Therapy

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 5523.

https://doi.org/10.1182/blood.V130.Suppl_1.5523.5523

Published: 2017

Journal Articles

Post-Autologous Stem Cell Transplantation Therapy for Multiple Myeloma Patients: Impact on Clinical Outcomes

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Sylvia McCulloch, MD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 5524.

https://doi.org/10.1182/blood.V130.Suppl_1.5524.5524

Published: 2017

Journal Articles

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 3151.

https://doi.org/10.1182/blood.V130.Suppl_1.3151.3151

Published: 2017

Journal Articles

Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)

Paola Neri, MD, Ines Tagoug, PhD, Ranjan Maity, PhD, Caleb K Stein, MS, Madison Kong, Jonathan Keats, PhD, David Soong, PhD, Christopher Chiu, PhD, P. Leif Bergsagel, MD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 63.

https://doi.org/10.1182/blood.V130.Suppl_1.63.63

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1836.

https://doi.org/10.1182/blood.V130.Suppl_1.1836.1836

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Immune Deregulation in Active Multiple Myeloma

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Monoclonal Gammopathy of Clinical Significance - a Single Center Experience

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns

Identification of Specificity Groups in Myeloma Patients T Cell Receptor (TCR) Repertoire through Single Cell TCR Sequencing

Enhancer Deregulation in Myeloma

Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients

Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

FOXM1 Is Associated with Development of Therapeutic Resistance in Multiple Myeloma

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Early Relapse in Transplant-Eligible MM Patients Undergoing Auto-SCT Followed By Maintenance Therapy

Post-Autologous Stem Cell Transplantation Therapy for Multiple Myeloma Patients: Impact on Clinical Outcomes

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)

Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)

Email alerts

ASH Publications

American Society of Hematology